Barclays Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1065
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Regeneron Pharmaceuticals but lowers the price target from $1080 to $1065.
November 01, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Regeneron Pharmaceuticals but lowers the price target from $1080 to $1065.
The Overweight rating suggests a positive outlook, but the lowered price target indicates a slight reduction in expected upside. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100